We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BLU

Price
-
Stock movement up
+- (%)
Company name
BELLUS Health Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
1.87B
Ent value
1.79B
Price/Sales
124613.93
Price/Book
5.07
Div yield
0.43%
Div growth
-46.86%
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
53.22%
1 year return
59.52%
3 year return
12.73%
5 year return
59.23%
10 year return
10.34%
Last updated: 2024-12-16

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share0.06
Dividend yield0.43%
Payout frequencyQuarterly
Maximum yield0.43%
Average yield0.43%
Minimum yield0.43%
Discount to avg yield-
Upside potential-
Yield as % of max yield100.00%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield0.43%
Current yield distribution-
Yield at 100% (Min)0.43%
Yield at 90%0.43%
Yield at 80%0.43%
Yield at 50% (Median)0.43%
Yield at 20%0.43%
Yield at 10%0.43%
Yield at 0% (Max)0.43%

Dividend per share

Dividend per share data
Years of growth-
CCC status-
Dividend per share0.06
Payout frequencyQuarterly
Ex-div date11 Mar 2011
EPS (TTM)-0.69
EPS (1y forward)-1.19
EPS growth (5y)53.22%
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
BLUS&P500
DGR MR-10.67%-13.74%
DGR TTM-57.98%6.60%
DGR 3 years-49.72%5.24%
DGR 5 years-46.86%5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced-
EPS growth (5y)53.22%
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward-5.34%-

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales124613.93
Price to Book5.07
EV to Sales119631.53

FINANCIALS

Per share

Per share data
Current share count126.81M
EPS (TTM)-0.69
FCF per share (TTM)-0.70

Income statement

Income statement data
Revenue (TTM)15.00K
Gross profit (TTM)15.00K
Operating income (TTM)-90.31M
Net income (TTM)-86.79M
EPS (TTM)-0.69
EPS (1y forward)-1.19

Margins

Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-214748.36%
Profit margin (TTM)-214748.36%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash85.38M
Net receivables990.00K
Total current assets327.71M
Goodwill0.00
Intangible assets50.10M
Property, plant and equipment0.00
Total assets379.54M
Accounts payable9.44M
Short/Current long term debt0.00
Total current liabilities9.80M
Total liabilities10.64M
Shareholder's equity368.90M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-89.22M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-89.22M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-23.53%
Return on Assets-22.87%
Return on Invested Capital-23.53%
Cash Return on Invested Capital-24.18%

STOCK INFORMATION

Downside potential

Downside potential data
BLUS&P500
Current price drop from All-time high-99.49%-7.10%
Highest price drop-99.98%-56.47%
Date of highest drop29 Jul 20169 Mar 2009
Avg drop from high-85.60%-11.07%
Avg time to new high119 days12 days
Max time to new high4146 days1805 days
COMPANY DETAILS
BLU (BELLUS Health Inc.) company logo
Marketcap
1.87B
Marketcap category
Small-cap
Description
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Employees
74
Website
https://www.bellushealth.com
Investor relations
-
SEC filings
BLU SEC filings
CEO
Roberto Bellini
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved